Document is current
Any future updates will be listed below
-
Authors
Weigel, Lucia
Wehr, Sophia
Galderisi, Silvana https://orcid.org/0000-0002-1592-7656
Mucci, Armida https://orcid.org/0000-0002-6195-9456
Davis, John https://orcid.org/0000-0003-3963-1654
Giordano, Giulia Maria https://orcid.org/0000-0002-5247-1117
Leucht, Stefan https://orcid.org/0000-0002-4934-4352
- License Information
-
More Information
Article History
Received: 28 April 2023
Accepted: 17 July 2023
First Online: 27 July 2023
Competing interests
: The authors declare the following competing interests: S.G. received advisory board/consultant fees, or honoraria/expenses from the following drug companies: Angelini, Boehringer Ingelheim, Gedeon Richter-Recordati, Innova Pharma-Recordati Group, Janssen, Lundbeck, Otsuka, Recordati Pharmaceuticals, Rovi Pharma and Sunovion Pharmaceuticals outside the submitted work. A.M. received advisory board or consultant fees from the following drug companies: Angelini, Gedeon. Richter Bulgaria, Janssen Pharmaceuticals, Lundbeck, Otsuka Pharmaceutical, Pfizer, Pierre Fabre, Rovi. Pharma and Boehringer Ingelheim outside the submitted work. S.L. has received honoraria as a consultant and/or advisor and/or for lectures and/or for educational material from Alkermes, Angelini, Eisai, Gedeon Richter, Janssen, Lundbeck, Medichem, Medscape, Merck Sharpp and Dome, Mitshubishi, Neurotorium, NovoNordisk, Otsuka, Recordati, Roche, Rovi, Sanofi Aventis, TEVA in the last three years. L.W., S.W., J.D. and G.M.G. have no conflict of interests to declare.
